NEW YORK (GenomeWeb News) – Rosetta Genomics announced today that its Rosetta Cancer Origin Test has received in-network provider status with Highmark Health Services.

Highmark Health is a subsidiary of Highmark and the fourth-largest Blue Cross Blue Shield-affiliated company, providing coverage for 5.3 million people in Pennsylvania, Delaware, and West Virginia. Its members now have access to Rosetta's test for identifying the tumor origin in cancer of unknown or uncertain primary as an in-network service.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.